The article says:
"After the investment is completed, the company will obtain the 50% underwriting right of the first phase of the Goulamina project with an annual production capacity of about 455,000 tons of spodumene concentrate. If the company directly provides financial assistance or assists LMSA to obtain debt funds provided by third-party banks or other financial institutions, it can obtain the underwriting right of the remaining 50% of the project's first phase."
So I'd say the "right" to purchase.
- Forums
- ASX - By Stock
- FFX
- Firefinch & GANFENG
Firefinch & GANFENG, page-30
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FFX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online